Core Viewpoint - The company Baiotai (688177.SH) has received a notice of acceptance for the marketing authorization application of its investigational drug, BAT4406F, from the National Medical Products Administration, indicating progress in its drug development pipeline [1]. Group 1: Drug Development - BAT4406F is a next-generation fully human anti-CD20 antibody developed using the company's antibody Fc engineering platform, featuring enhanced ADCC (antibody-dependent cellular cytotoxicity) capabilities [1]. - The drug specifically binds to CD20 molecules on B cells and precursor cells, as well as having high affinity for NK (natural killer) cells, which induces biological effects to eliminate B cells [1]. - As of the announcement date, a Phase II/III registration clinical study for BAT4406F targeting minimal change disease/focal segmental glomerulosclerosis (MCD/FSGS) is ongoing, marking the first registration study for this indication in China [1]. Group 2: Regulatory Status - The approval process for BAT4406F is still ongoing, and the timeline for the completion of the review and approval cannot be estimated at this time [1]. - The receipt of the marketing authorization application acceptance notice will not have an immediate impact on the company's recent performance [1].